Cite
HARVARD Citation
Sanborn, R. et al. (2015). Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].